Full Text Journal Articles by
Author Thomas V Jones

Advertisement

Find full text journal articles








Worldwide post-marketing safety surveillance experience with tofacitinib in ulcerative colitis.

David T Rubin, Irene Modesto, Séverine Vermeire, Silvio Danese, Siew C Ng, Kenneth K Kwok, Nana Koram, Thomas V Jones,

<h4>Background</h4>Tofacitinib is an oral Janus kinase inhibitor for the treatment of ulcerative colitis (UC). Post-marketing surveillance (PMS) is an important part of monitoring adverse events (AEs).<h4>Aims</h4>To report an analysis of PMS case safety reports for tofacitinib in patients with UC METHODS: Worldwide tofacitinib PMS reports received in the Pfizer safety ... Read more >>

Aliment Pharmacol Ther (Alimentary pharmacology & therapeutics)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposure.

Gerd R Burmester, Peter Nash, Bruce E Sands, Kim Papp, Lori Stockert, Thomas V Jones, Huaming Tan, Ann Madsen, Hernan Valdez, Stanley B Cohen,

<h4>Objectives</h4>To analyse adverse events (AEs) of special interest across tofacitinib clinical programmes in rheumatoid arthritis (RA), psoriatic arthritis (PsA), ulcerative colitis (UC) and psoriasis (PsO), and to determine whether the incidence rates (IRs; unique patients with events per 100 patient-years) of these events are consistent across diseases.<h4>Methods</h4>The analysis included data ... Read more >>

RMD Open (RMD open)
[2021, 7(2):]

Cited: 0 times

View full text PDF listing >>



Advertisement

Correspondence on 'EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update'.

Lara Fallon, Thomas V Jones,

Ann Rheum Dis (Annals of the rheumatic diseases)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data.

Philip Mease, Christina Charles-Schoeman, Stanley Cohen, Lara Fallon, John Woolcott, Huifeng Yun, Joel Kremer, Jeffrey Greenberg, Wendi Malley, Alina Onofrei, Keith S Kanik, Daniela Graham, Cunshan Wang, Carol Connell, Hernan Valdez, Manfred Hauben, Eric Hung, Ann Madsen, Thomas V Jones, Jeffrey R Curtis,

<h4>Objectives</h4>Tofacitinib is a Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ulcerative colitis, and has been investigated in psoriasis (PsO). Routine pharmacovigilance of an ongoing, open-label, blinded-endpoint, tofacitinib RA trial (Study A3921133; NCT02092467) in patients aged ≥50 years and with ≥1 cardiovascular risk factor ... Read more >>

Ann Rheum Dis (Annals of the rheumatic diseases)
[2020, 79(11):1400-1413]

Cited: 24 times

View full text PDF listing >>



Letter: thromboembolic and cardiovascular events with tofacitinib in ulcerative colitis-two cases in real world clinical practice. Authors' reply.

William J Sandborn, Julian Panés, Bruce E Sands, Walter Reinisch, Chinyu Su, Nervin Lawendy, Nana Koram, Haiyun Fan, Thomas V Jones, Irene Modesto, Daniel Quirk, Silvio Danese,

Aliment Pharmacol Ther (Alimentary pharmacology & therapeutics)
[2020, 51(11):1209-1210]

Cited: 0 times

View full text PDF listing >>



Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme.

William J Sandborn, Julian Panés, Bruce E Sands, Walter Reinisch, Chinyu Su, Nervin Lawendy, Nana Koram, Haiyun Fan, Thomas V Jones, Irene Modesto, Daniel Quirk, Silvio Danese,

<h4>Background</h4>Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of ulcerative colitis (UC).<h4>Aim</h4>To report incidence of deep vein thrombosis (DVT) and pulmonary embolism (PE) in the tofacitinib UC programme.<h4>Methods</h4>DVT and PE were evaluated from one phase 2 and two phase 3 induction studies, one phase 3 maintenance study ... Read more >>

Aliment Pharmacol Ther (Alimentary pharmacology & therapeutics)
[2019, 50(10):1068-1076]

Cited: 29 times

View full text PDF listing >>



Outcomes of Pregnancies With Maternal/Paternal Exposure in the Tofacitinib Safety Databases for Ulcerative Colitis.

Uma Mahadevan, Marla C Dubinsky, Chinyu Su, Nervin Lawendy, Thomas V Jones, Amy Marren, Haiying Zhang, Daniela Graham, Megan E B Clowse, Steven R Feldman, Daniel C Baumgart,

<h4>Background</h4>Active inflammatory bowel disease increases the risk of adverse pregnancy outcomes. Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). As a small molecule, tofacitinib is likely to cross the placental barrier; however, information on the effects of tofacitinib on pregnancy outcomes is ... Read more >>

Inflamm Bowel Dis (Inflammatory bowel diseases)
[2018, 24(12):2494-2500]

Cited: 29 times

View full text PDF listing >>



Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial.

Josef S Smolen, Annette Szumski, Andrew S Koenig, Thomas V Jones, Lisa Marshall,

BACKGROUND:The aim was to analyze characteristics that predict remission induction and subsequent loss of remission in patients with moderately active rheumatoid arthritis (RA) who received full-dose combination etanercept plus methotrexate induction therapy followed by reduced-dose etanercept or etanercept withdrawal. METHODS:Patients with Disease Activity Score based on 28-joint count (DAS28) >3.2 ... Read more >>

Arthritis Res Ther (Arthritis research & therapy)
[2018, 20(1):8]

Cited: 10 times

View full text PDF listing >>



Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritis.

Jeffrey R Curtis, Hendrik Schulze-Koops, Liza Takiya, Charles A Mebus, Ketti K Terry, Pinaki Biswas, Thomas V Jones,

<h4>Objectives</h4>Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We evaluated the efficacy and safety of tofacitinib 5 or 10 mg twice daily (BID), in patients with moderate to severe RA, aged ≥65 and <65 years.<h4>Methods</h4>Data were pooled from five Phase 3 trials and, separately, ... Read more >>

Clin Exp Rheumatol (Clinical and experimental rheumatology)
[2017, 35(3):390-400]

Cited: 14 times

View full text PDF listing >>



Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis.

Mark C Genovese, Ronald F van Vollenhoven, Bethanie Wilkinson, Lisy Wang, Samuel H Zwillich, David Gruben, Pinaki Biswas, Richard Riese, Liza Takiya, Thomas V Jones,

<h4>Background</h4>Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). The aim of this study was to explore the safety and efficacy of open-label tofacitinib following blinded treatment with adalimumab or tofacitinib for moderate to severe RA.<h4>Methods</h4>Analyses included patients treated with adalimumab 40 mg once every 2 weeks ... Read more >>

Arthritis Res Ther (Arthritis research & therapy)
[2016, 18:145]

Cited: 4 times

View full text PDF listing >>



Discordance between patient and physician assessments of global disease activity in rheumatoid arthritis and association with work productivity.

Josef S Smolen, Vibeke Strand, Andrew S Koenig, Annette Szumski, Sameer Kotak, Thomas V Jones,

<h4>Background</h4>Discordance between patient and physician ratings of rheumatoid arthritis (RA) severity occurs in clinical practice and correlates with pain scores and measurements of joint disease. However, information is lacking on whether discordance impacts patients' ability to work. We evaluated the discordance between patient and physician ratings of RA disease activity ... Read more >>

Arthritis Res Ther (Arthritis research & therapy)
[2016, 18(1):114]

Cited: 22 times

View full text PDF listing >>





Advertisement


Disclaimer

1.5261 s